New Real-World study tracks fabry Drug's Long-Term impact on heart and kidneys

NCT ID NCT07109375

Recruiting now Disease control Sponsor: Chiesi Italia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study follows 75 adults with Fabry disease who are taking or starting pegunigalsidase alfa to see how well it works and how safe it is over time in real-world settings. Researchers will check heart structure and function, kidney health, and exercise capacity. The goal is to understand if this enzyme replacement therapy helps control the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fabry disease lysosomal storage disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FABRY DISEASE

Contacts and locations

Locations

A.O. Sant'Anna e San Sebastiano
NOT_YET_RECRUITING

Caserta, Italy
A.O.U. Policlinico "Giaccone"
NOT_YET_RECRUITING

Palermo, Italy
AOU Federico II, Dipartimento di Nefrologia
NOT_YET_RECRUITING

Naples, Italy
AUSL Toscana Sud-Est - Ospedale San Donato
NOT_YET_RECRUITING

Arezzo, Italy
Azienda Ospedaliera Universitaria Consorziale Policlinico Di Bari
RECRUITING

Bari, Italy
Irccs Azienda Ospedaliero-Universitaria Di Bologna - Policlinico Di Sant'Orsola
RECRUITING

Bologna, Italy
U.O.C. Nefrologia ASST Monza - Ospedale San Gerardo
NOT_YET_RECRUITING

Monza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.